A retrospective study assessing HBeAg seroconversion during treatment with peginterferon- alfa2a (PEG-IFN) is preceded by selection of hepatitis B virus basal core promoter and pre-core variants which are associated with decreased HBV replication
Latest Information Update: 16 Oct 2020
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- Acronyms WV16241
- 16 Oct 2020 New trial record
- 29 Aug 2020 Results presented at The International Liver Congress 2020